E-α-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile | 297744-40-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: E-α-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile
• 英文别名: (E)-3-Amino-3-((4-aminophenyl)thio)-2-(2-(trifluoromethyl)phenyl)acrylonitrile；(E)-3-amino-3-(4-aminophenyl)sulfanyl-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile
• CAS: 297744-40-2
• 化学式: C₁₆H₁₂F₃N₃S
• 分子量: 335.353
• InChiKey: JLOXTZFYJNCPIS-SQFISAMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-[2-[(trifluoromethyl)phenyl]]propanedinitrile 、 4-氨基苯硫酚 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 (2Z)-3-amino-3-[(4-aminophenyl)sulfanyl]-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile 、 E-α-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile
  参考文献：
  名称：

  Amino-thio-acrylonitriles as MEK inhibitors

  摘要：

  这项发明通常涉及式Ia或Ib的氨基硫基丙烯腈：作为MEK抑制剂，含有该化合物的药物组合物，以及使用该化合物用于治疗和预防炎症性疾病或作为抗癌放射增敏剂的方法。

  公开号：

  US06703420B1

文献信息

• Methods for treating seizure disorders by inhibiting MAPK pathway activation
  申请人：——

  公开号：US20020058699A1

  公开（公告）日：2002-05-16

  Excessive brain neuronal excitability, associated with a seizure disorder, can be correlated with increased mitogen-activated protein kinase (MAPK) activity in neurons. Such excessive excitability can be ameliorated by administering an effective amount of a compound, such as a MAPK phosphorylation or kinase activity inhibitor, that reduces the amount of MAPK activity in neurons of an individual suffering from a seizure disorder. Compounds that inhibit phosphorylation or kinase activity of upstream activators or downstream targets of the MAPK cascade also are useful in this context.

  过度的脑神经兴奋，与癫痫病有关，可能与神经元中丝裂原活化蛋白激酶（MAPK）的活性增加相关。通过给患有癫痫病的个体施用有效量的化合物，如MAPK磷酸化或激酶活性抑制剂，可以减少神经元中MAPK活性的数量，从而改善这种过度的兴奋。抑制MAPK级联的上游激活剂或下游靶标的磷酸化或激酶活性的化合物在这种情况下也是有用的。
• METHODS FOR TREATING AND/OR PREVENTING CARDIOMYOPATHIES BY ERK OR JNK INHIBITION
  申请人：Worman Howard J.

  公开号：US20110110916A1

  公开（公告）日：2011-05-12

  Provided is a method of treating or preventing a cardiomyopathy associated with activation of at least one kinase in the MAP kinase signaling pathway in heart tissue by providing to a subject an inhibitor of at least one kinase in the ERK signaling pathway or in the JNK signaling pathway, or both. In some embodiments, the cardiomyopathy is associated with one or more mutations in the LMNA gene, which encodes A-type nuclear lamins, or in the EMD gene, which encodes an inner nuclear membrane protein.
• Methods of Treating Hepatitis C Virus Infection
  申请人：Ott Melanie

  公开号：US20110110891A1

  公开（公告）日：2011-05-12

  The present disclosure provides methods of treating a hepatitis C virus infection. The methods generally involve administering to an individual in need thereof an effective amount of an active agent that inhibits a RAS-RAF-MEK-ERK signal transduction pathway.
• Methods of Treating Seizure Disorders
  申请人：Massachusetts Institute of Technology

  公开号：US20130225671A1

  公开（公告）日：2013-08-29

  Seizure disorders are treated by Ras inhibitors. In an embodiment, the Ras inhibitor includes a farnesyl transferase inhibitor. In another embodiment, the farnesyl transferase inhibitor includes a 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor. In another embodiment, the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor is not a Ras inhibitor. Subjects having fragile X syndrome, autism, Angelman syndrome, Costello syndrome, cardio facio cutaneous syndrome, neurofibromatosis type I, Noonan syndrome and Coffin-Lowry syndrome that have seizure disorders can be treated.
• US6703420B1
  申请人：——

  公开号：US6703420B1

  公开（公告）日：2004-03-09